Goldman Sachs' downgrade and reduced price target for Cue Health's stock directly impacts the stock's short-term performance. The downgrade from Buy to Neutral indicates a less favorable outlook, while the lowered price target from $2.75 to $0.75 suggests a significant decrease in the stock's perceived value. This news is likely to cause a negative sentiment among investors, leading to a decline in the stock's price in the short term.